Revising the concept of efficacy in the vocal therapy of neurodegenerative diseases

Revisión del concepto de eficacia en el tratamiento vocal de las enfermedades neurodegenerativas; Revising the concept of efficacy in the vocal therapy of neurodegenerative diseases; Rosa M. Bermúdez de Alvear, A. Ginés Martínez Arquero; Revista de Logopedia, Foniatría y Audiología, Available online 10 September 2012

Keywords: Dysarthria, Laryngeal dysfunction, Treatment efficacy, Neurodegenerative diseases, Parkinson's disease, Respiratory insufficiency, Therapeutic outcomes, Voice and speech therapy

Palabras clave: Disartria, Disfunción laríngea, Eficacia terapéutica, Enfermedades neurodegenerativas, Enfermedad de Parkinson, Insuficiencia respiratoria, Resultados terapéuticos, Terapia vocal y del habla

Abstracts presented at the American Society of Gene & Cell Therapy’s 15th Annual Meeting, 2012, Philadelphia, Pennsylvania

317. AAV Based Gene Therapy Rescues the Murine Cardiac Phenotype Associated with Friedreich’s Ataxia
 Hélène Puccio, Brahim Belbellaa, Morgane Perdomini, Nathalie Cartier, Patrick Aubourg.


436. A Recombinant Frataxin Protein Fused witha Cell Penetrating Peptide Prevents the Death ofFibroblasts with Knock-Out Frataxin Genes
Jacques P. Tremblay,1 Zoé Coulombe,1 Pierre Chapdelaine.1

784. TALE proteins may be used to induce specific gene expression to treat some diseases

Jacques P. Tremblay, Pierre Chapdelaine, Zoé Coulombe, Joel Rousseau

835. Prospects for the Gene Therapy of Friereich’s Ataxia using Neurotrophic Factors

Yurika Katsu, Frida Loria and Javier Diaz-Nido

Will the floodgates open for gene therapy?

Nature Biotechnology 30, 805 (2012), doi:10.1038/nbt.2363 Published online, 10 September 2012

EDITORIAL.
In a matter of days, a momentous event will occur: a gene therapy will, for the first time anywhere in the Western hemisphere, be available commercially with full marketing approval. read more....